SCLC-I subtype tends to be more responsive to immunotherapy, similarly to SCLC-Y subtype since YAP1 upregulates PD-L1 expression and induces an immunosuppressive TME [83, 84]. This evidence concerns the gene YAP1 and small cell lung carcinoma.